Abstract
Blood monocytes which differentiate into tissue macrophages, are unique in that they can not only initiate immune responses but can also be effector cells which contribute to the resolution of these responses. There is no single activation phenotype, and macrophages can be induced to differentiate into cells that either exacerbate or inhibit acute inflammation. Similarly, these cells can promote, deviate or suppress adaptive immune responses. This review focuses on the mechanisms that have been implicated in the recruitment, activation and differentiation of inflammatory monocytes / macrophages in chronic inflammatory bowel diseases, i.e. ulcerative colitis and Crohns disease. These mechanisms might provide attractive targets for novel therapies.
Keywords: inflammatory bowel disease, crohns disease, ulcerative colitis, monocyte, macrophage
Current Drug Targets - Inflammation & Allergy
Title: Macrophages in Inflammatory Bowel Disease
Volume: 2 Issue: 2
Author(s): Olof Grip, Sabina Janciauskiene and Stefan Lindgren
Affiliation:
Keywords: inflammatory bowel disease, crohns disease, ulcerative colitis, monocyte, macrophage
Abstract: Blood monocytes which differentiate into tissue macrophages, are unique in that they can not only initiate immune responses but can also be effector cells which contribute to the resolution of these responses. There is no single activation phenotype, and macrophages can be induced to differentiate into cells that either exacerbate or inhibit acute inflammation. Similarly, these cells can promote, deviate or suppress adaptive immune responses. This review focuses on the mechanisms that have been implicated in the recruitment, activation and differentiation of inflammatory monocytes / macrophages in chronic inflammatory bowel diseases, i.e. ulcerative colitis and Crohns disease. These mechanisms might provide attractive targets for novel therapies.
Export Options
About this article
Cite this article as:
Grip Olof, Janciauskiene Sabina and Lindgren Stefan, Macrophages in Inflammatory Bowel Disease, Current Drug Targets - Inflammation & Allergy 2003; 2 (2) . https://dx.doi.org/10.2174/1568010033484179
DOI https://dx.doi.org/10.2174/1568010033484179 |
Print ISSN 1568-010X |
Publisher Name Bentham Science Publisher |
Online ISSN 1568-010X |
Related Articles
-
Genetics and Ulcerative Colitis: What are the Clinical Implications?
Current Drug Targets Epigenetic Modifications of the Nuclear Factor Kappa B Signalling Pathway and its Impact on Inflammatory Bowel Disease
Current Pharmaceutical Design Guar Gum and HPMC Coated Colon Targeted Delivery of 6-Mercapto-Purine
The Natural Products Journal Risk Factors for Serious Adverse Effects of Thiopurines in Patients with Crohn’s Disease
Current Drug Safety Diagnosis of Inflammatory Bowel Disease by Abdominal Ultrasound and Color Doppler Techniques
Current Medical Imaging Colon as Target for Drug Delivery
Current Drug Therapy Use of Synbiotics for Ulcerative Colitis Treatment
Current Clinical Pharmacology Immunomodulatory Activity of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Immune Abnormalities and Endotoxemia in Patients with Ulcerative Colitis and in Their First Degree Relatives: Attempts at Neutralizing Endotoxin- Mediated Effects
Current Pharmaceutical Design Patients’ Induced Pluripotent Stem Cells to Model Drug Induced Adverse Events: A Role in Predicting Thiopurine Induced Pancreatitis?
Current Drug Metabolism Ulcerative Colitis: Pathogenesis
Current Drug Targets Novel MicroRNA Signature to Differentiate Ulcerative Colitis from Crohn Disease: A Genome-Wide Study Using Next Generation Sequencing
MicroRNA Role of Inflammation in the Development of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Probiotic Lactobacilli: A New Perspective for the Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design Color Doppler Ultrasound Assessment of Clinical Activity in Inflammatory Bowel Disease
Current Medical Imaging Randomized Controlled Trials in Prevention of PostSurgical Recurrence in Crohn’s Disease
Reviews on Recent Clinical Trials Differential Expression of miR-31 between Inflammatory Bowel Disease and Microscopic Colitis
MicroRNA New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists
Current Pharmaceutical Design Alternative Therapy in the Prevention of Experimental and Clinical Inflammatory Bowel Disease. Impact of Regular Physical Activity, Intestinal Alkaline Phosphatase and Herbal Products
Current Pharmaceutical Design Desirability Based Optimization of New Mesalazine Modified Release Formulations: Compression Coated Tablets and Mini Tablets in Capsules
Letters in Drug Design & Discovery